AtriCure Q3 2026: A 1,328% EPS Beat and What Comes Next
As seen on the 24/7 Wall St. homepage on November 3, 2026.
A company Wall Street expected to barely break even just delivered adjusted EPS of $0.17, beating expectations. Management now sees full-year revenue of $606 million to $610 million, so the profitability turn in cardiac ablation and pain management is no longer a one-quarter fluke.
Continue ReadingShow less
AtriCure posted adjusted diluted EPS of $0.17 for Q3 2026 against a Wall Street consensus of just $0.01, a beat of more than 1,328%. Revenue came in ahead of estimates and climbed 15% year over year, led by the cryoSPHERE MAX probe in post-operative pain management and AtriClip device sales in appendage management.
The profitability story has been building for several quarters: AtriCure was still reporting losses as recently as Q3 2025. The turn to consistent positive earnings began in Q4 2025 and has now produced three straight quarters of adjusted profits, suggesting the improvement is structural rather than seasonal.
Sponsored
Gross margin expanded 180 basis points to 77.3% on a favorable mix of products and geographies, and adjusted EBITDA surged 51%. The BoxX-NoAF clinical trial, which management highlighted as advancing rapidly, is a future catalyst for the cardiac ablation franchise, though R&D spending rose as that work accelerates.
Management raised the stakes for the full year with guidance for adjusted EPS of $0.40 to $0.46, alongside higher revenue and adjusted EBITDA. Those figures imply that Q3's profitability was not a one-quarter anomaly, and that AtriCure expects positive cash generation to continue through year-end. CEO Michael Carrel framed the results around portfolio breadth and disciplined execution, noting that adoption of the company's technologies is driving both growth and expanding profitability.
Mentioned: ATRC